Interindividual variability in oral antidiabetic drug disposition and response: The role of drug transporter polymorphisms

Expert Opinion on Drug Metabolism and Toxicology

Volumn 4, Issue 5, 2008, Pages 529-544

  Pacanowski, Michael A ^a   Hopley, Charles W ^a   Aquilante, Christina L ^b  

^a UNIVERSITY OF FLORIDA   (United States)

^b UNIVERSITY OF COLORADO   (United States)

Author keywords

Drug transporter; Oral antidiabetic; Pharmacogenetic; Pharmacogenomic

Indexed keywords

ALPHA GLUCOSIDASE INHIBITOR; BIGUANIDE DERIVATIVE; CHLORPROPAMIDE; CLARITHROMYCIN; CYCLOSPORIN A; CYTOCHROME P450 2C9; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GEMFIBROZIL; GLIBENCLAMIDE; GLIPIZIDE; GLITAZONE DERIVATIVE; HEMOGLOBIN A1C; MEGLITINIDE; METFORMIN; NATEGLINIDE; OCTAMER TRANSCRIPTION FACTOR 1; OCTAMER TRANSCRIPTION FACTOR 2; ORAL ANTIDIABETIC AGENT; ORGANIC ANION TRANSPORTER 1; ORGANIC ANION TRANSPORTER 2; ORGANIC CATION TRANSPORTER; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONIST; PIOGLITAZONE; REPAGLINIDE; RIFAMPICIN; ROSIGLITAZONE; SITAGLIPTIN; SULFONYLUREA DERIVATIVE; UNINDEXED DRUG; VERAPAMIL;

AREA UNDER THE CURVE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DOSAGE SCHEDULE COMPARISON; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG RESPONSE; DRUG TARGETING; DRUG TRANSPORT; FOOD DRUG INTERACTION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; GRAPEFRUIT JUICE; HUMAN; HYPOGLYCEMIA; INSULIN SENSITIVITY; MEDLINE; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PHARMACOGENETICS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TRANSPORT; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; WEIGHT GAIN;

ADMINISTRATION, ORAL; ANIMALS; CARRIER PROTEINS; HUMANS; HYPOGLYCEMIC AGENTS; POLYMORPHISM, GENETIC; TISSUE DISTRIBUTION;

EID: 45949086577     PISSN: 17425255     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425255.4.5.529     Document Type: Review

References (120)

1. International Diabetes Federation website. Available from: http://www.idf.org [Last accessed 30 January 2008]
2. Stumvoll M, Goldstein BJ, van Haeften TW. Type 2 diabetes: principles of pathogenesis and therapy. Lancet 2005;365:1333-46
3. American Diabetes Association. Standards of medical care in diabetes: 2008. Diabetes Care 2008;31:S12-54
4. Bolen S, Feldman L, Vassy J, et al. Systematic review: comparative effectiveness and safety of oral medications for type 2 diabetes mellitus. Ann Intern Med 2007;147:386-99
5. Nathan DM, Buse JB, Davidson MB, et al. Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2006;29:1963-72
6. Kahn SE, Haffner SM, Heise MA, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006;355:2427-43
7. Nathan DM, Buse JB, Davidson MB, et al. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: update regarding thiazolidinediones: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2008;31:173-5
8. Kirchheiner J, Roots I, Goldammer M, et al. Effect of genetic polymorphisms in cytochrome p450 (CYP) 2C9 and CYP2C8 on the pharmacokinetics of oral antidiabetic drugs: clinical relevance. Clin Pharmacokinet 2005;44:1209-25
9. Aquilante CL. Pharmacogenetics of thiazolidinedione therapy. Pharmacogenomics 2007;8:917-31
10. Bozkurt O, de Boer A, Grobbee DE, et al. Pharmacogenetics of glucose-lowering drug treatment: a systematic review. Mol Diagn Ther 2007;11:291-302
11. Moore AF, Florez JC. Genetic susceptibility to type 2 diabetes and implications for antidiabetic therapy. Ann Rev Med 2008;59:95-111
12. Ho RH, Kim RB. Transporters and drug therapy: implications for drug disposition and disease. Clin Pharmacol Ther 2005;78:260-77
13. Shitara Y, Horie T, Sugiyama Y. Transporters as a determinant of drug clearance and tissue distribution. Eur J Pharm Sci 2006;27:425-46
14. Bachmakov I, Glaeser H, Fromm MF, et al. Interaction of oral antidiabetic drugs with hepatic uptake transporters: focus on OATPs and OCT1. Diabetes 2008 Feb 26 [Epub ahead of print] PMID: 18314419
15. Bailey CJ, Turner RC. Metformin. N Engl J Med 1996;334:574-9
16. Reitman ML, Schadt EE. Pharmacogenetics of metformin response: a step in the path toward personalized medicine. J Clin Invest 2007;117:1226-9
17. Glucophage prescribing information. Bristol-Myers Squibb Company; 2006
18. Kirpichnikov D, McFarlane SI, Sowers JR. Metformin: an update. Ann Intern Med 2002;137:25-33
19. Hundal RS, Krssak M, Dufour S, et al. Mechanism by which metformin reduces glucose production in type 2 diabetes. Diabetes 2000;49:2063-9
20. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998;352:854-65
21. Inzucchi SE. Oral antihyperglycemic therapy for type 2 diabetes: scientific review. JAMA 2002;287:360-72
22. Hermann LS, Schersten B, Bitzen PO, et al. Therapeutic comparison of metformin and sulfonylurea, alone and in various combinations. A double-blind controlled study. Diabetes Care 1994;17:1100-9
23. Riedel AA, Heien H, Wogen J, et al. Loss of glycemic control in patients with type 2 diabetes mellitus who were receiving initial metformin, sulfonylurea, or thiazolidinedione monotherapy. Pharmacotherapy 2007;27:1102-10
24. Pearson ER, Donnelly LA, Kimber C, et al. Variation in TCF7L2 influences therapeutic response to sulfonylureas: a GoDARTs study. Diabetes 2007;56:2178-82
25. Turner RC, Cull CA, Frighi V, et al. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA 1999;281:2005-12
26. Sambol NC, Chiang J, O'Conner M, et al. Pharmacokinetics and pharmacodynamics of metformin in healthy subjects and patients with noninsulin-dependent diabetes mellitus. J Clin Pharmacol 1996;36:1012-21
27. Sirtori CR, Franceschini G, Galli-Kienle M, et al. Disposition of metformin (N,N-dimethylbiguanide) in man. Clin Pharmacol Ther 1978;24:683-93
28. Pentikainen PJ, Neuvonen PJ, Penttila A. Pharmacokinetics of metformin after intravenous and oral administration to man. Eur J Clin Pharmacol 1979;16:195-202
29. Tucker GT, Casey C, Phillips PJ, et al. Metformin kinetics in healthy subjects and in patients with diabetes mellitus. Br J Clin Pharmacol 1981;12:235-46
30. Shu Y, Brown C, Castro R, et al. Effect of genetic variation in the organic cation transporter 1, OCT1, on metformin pharmacokinetics. Mol Ther 2008;83:273-80
31. Wang DS, Jonker JW, Kato Y, et al. Involvement of organic cation transporter 1 in hepatic and intestinal distribution of metformin. J Pharmacol Exp Ther 2002;302:510-5
32. Scheen AJ. Clinical pharmacokinetics of metformin. Clin Pharmacokinet 1996;30:359-71
33. Leabman MK, Huang CC, DeYoung J, et al. Natural variation in human membrane transporter genes reveals evolutionary and functional constraints. Proc Natl Acad Sci USA 2003;100:5896-901
34. Kimura N, Masuda S, Tanihara Y, et al. Metformin is a superior substrate for renal organic cation transporter OCT2 rather than hepatic OCT1. Drug Metab Pharmacokinet 2005;20:379-86
35. Zhang L, Dresser MJ, Gray AT, et al. Cloning and functional expression of a human liver organic cation transporter. Mol Pharmacol 1997;51:913-21
36. Dresser MJ, Leabman MK, Giacomini KM. Transporters involved in the elimination of drugs in the kidney: organic anion transporters and organic cation transporters. J Pharm Sci 2001;90:397-421
37. Dresser MJ, Xiao G, Leabman MK, et al. Interactions of n-tetraalkylammonium compounds and biguanides with a human renal organic cation transporter (hOCT2). Pharm Res 2002;19:1244-7
38. Shu Y, Sheardown SA, Brown C, et al. Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action. J Clin Invest 2007;117:1422-31
39. Wang DS, Kusuhara H, Kato Y, et al. Involvement of organic cation transporter 1 in the lactic acidosis caused by metformin. Mol Pharmacol 2003;63:844-8
40. Sakata T, Anzai N, Shin HJ, et al. Novel single nucleotide polymorphisms of organic cation transporter 1 (SLC22A1) affecting transport functions. Biochem Biophys Res Commun 2004;313:789-93
41. Shu Y, Leabman MK, Feng B, et al. Evolutionary conservation predicts function of variants of the human organic cation transporter, OCT1. Proc Natl Acad Sci USA 2003;100:5902-7
42. Kerb R, Brinkmann U, Chatskaia N, et al. Identification of genetic variations of the human organic cation transporter hOCT1 and their functional consequences. Pharmacogenetics 2002;12:591-5
43. Shikata E, Yamamoto R, Takane H, et al. Human organic cation transporter (OCT1 and OCT2) gene polymorphisms and therapeutic effects of metformin. J Hum Genet 2007;52:117-22
44. Fujita T, Urban TJ, Leabman MK, et al. Transport of drugs in the kidney by the human organic cation transporter, OCT2 and its genetic variants. J Pharm Sci 2006;95:25-36
45. Shu Y, Urban TJ, Leabman MK, et al. PharmGKB submission update: V. PMT submissions of genetic variation in SLC22 family transporters. Pharmacol Rev 2006;58:3-4
46. Florez JC, Jablonski KA, Sun MW, et al. Effects of the type 2 diabetes-associated PPARG P12A polymorphism on progression to diabetes and response to troglitazone. J Clin Endocrinol Metab 2007;92:1502-9
47. Florez JC, Jablonski KA, Kahn SE, et al. Type 2 diabetes-associated missense polymorphisms KCNJ11 E23K and ABCC8 A1369S influence progression to diabetes and response to interventions in the Diabetes Prevention Program. Diabetes 2007;56:531-6
48. Prandin Prescribing Information. Novo Nordisk, Inc.; 2006
49. Starlix Prescribing Information. Novartis; 2006
50. Hatorp V. Clinical pharmacokinetics and pharmacodynamics of repaglinide. Clin Pharmacokinet 2002;41:471-83
51. Dornhorst A. Insulinotropic meglitinide analogues. Lancet 2001;358:1709-16
52. Rosenstock J, Hassman DR, Madder RD, et al. Repaglinide versus nateglinide monotherapy: a randomized, multicenter study. Diabetes Care 2004;27:1265-70
53. Niemi M, Backman JT, Neuvonen M, et al. Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics and pharmacodynamics of repaglinide: potentially hazardous interaction between gemfibrozil and repaglinide. Diabetologia 2003;46:347-51
54. Niemi M, Neuvonen PJ, Kivisto KT. The cytochrome P4503A4 inhibitor clarithromycin increases the plasma concentrations and effects of repaglinide. Clin Pharmacol Ther 2001;70:58-65
55. Zhang W, He YJ, Han CT, et al. Effect of SLCO1B1 genetic polymorphism on the pharmacokinetics of nateglinide. Br J Clin Pharmacol 2006;62:567-72
56. Kirchheiner J, Meineke I, Muller G, et al. Influence of CYP2C9 and CYP2D6 polymorphisms on the pharmacokinetics of nateglinide in genotyped healthy volunteers. Clin Pharmacokinet 2004;43:267-78
57. Thomsen MS, Chassard D, Evene E, et al. Pharmacokinetics of repaglinide in healthy caucasian and Japanese subjects. J Clin Pharmacol 2003;43:23-8
58. McLeod JF. Clinical pharmacokinetics of nateglinide: a rapidly-absorbed, short-acting insulinotropic agent. Clin Pharmacokinet 2004;43:97-120
59. Konig J, Seithel A, Gradhand U, et al. Pharmacogenomics of human OATP transporters. Naunyn Schmiedebergs Arch Pharmacol 2006;372:432-43
60. Tirona RG, Leake BF, Merino G, et al. Polymorphisms in OATP-C: identification of multiple allelic variants associated with altered transport activity among European- and African-Americans. J Biol Chem 2001;276:35669-75
61. Kameyama Y, Yamashita K, Kobayashi K, et al. Functional characterization of SLCO1B1 (OATP-C) variants, SLCO1B1*5, SLCO1B1*15 and SLCO1B1*15+C1007G, by using transient expression systems of HeLa and HEK293 cells. Pharmacogenet Genomics 2005;15:513-22
62. Kivisto KT, Niemi M. Influence of drug transporter polymorphisms on pravastatin pharmacokinetics in humans. Pharm Res 2007;24:239-47
63. Mwinyi J, Johne A, Bauer S, et al. Evidence for inverse effects of OATP-C (SLC21A6) 5 and 1b haplotypes on pravastatin kinetics. Clin Pharmacol Ther 2004;75:415-21
64. Iwai M, Suzuki H, Ieiri I, et al. Functional analysis of single nucleotide polymorphisms of hepatic organic anion transporter OATP1B1 (OATP-C). Pharmacogenetics 2004;14:749-57
65. Maeda K, Ieiri I, Yasuda K, et al. Effects of organic anion transporting polypeptide 1B1 haplotype on pharmacokinetics of pravastatin, valsartan, and temocapril. Clin Pharmacol Ther 2006;79:427-39
66. Niemi M, Schaeffeler E, Lang T, et al. High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1). Pharmacogenetics 2004;14:429-40
67. Kajosaari LI, Niemi M, Neuvonen M, et al. Cyclosporine markedly raises the plasma concentrations of repaglinide. Clin Pharmacol Ther 2005;78:388-99
68. Niemi M, Backman JT, Kajosaari LI, et al. Polymorphic organic anion transporting polypeptide 1B1 is a major determinant of repaglinide pharmacokinetics. Clin Pharmacol Ther 2005;77:468-78
69. Niemi M, Leathart JB, Neuvonen M, et al. Polymorphism in CYP2C8 is associated with reduced plasma concentrations of repaglinide. Clin Pharmacol Ther 2003;74:380-7
70. Kalliokoski A, Neuvonen M, Neuvonen PJ, et al. Different effects of SLCO1B1 polymorphism on the pharmacokinetics and pharmacodynamics of repaglinide and nateglinide. J Clin Pharmacol 2008
71. Actos Prescribing Information. Takeda Pharmaceuticals America, Inc.; 2007
72. Avandia Prescribing Information. GlaxoSmithKline; 2007
73. Yki-Jarvinen H. Thiazolidinediones. N Engl J Med 2004;351:1106-18
74. Balfour JA, Plosker GL. Rosiglitazone. Drugs 1999;57:921-30; discussion 31-2
75. Gillies PS, Dunn CJ. Pioglitazone. Drugs 2000;60:333-43; discussion 44-5
76. Kalliokoski A, Neuvonen M, Neuvonen PJ, et al. No significant effect of SLCO1B1 polymorphism on the pharmacokinetics of rosiglitazone and pioglitazone. Br J Clin Pharmacol 2008;65:78-86
77. Bluher M, Lubben G, Paschke R. Analysis of the relationship between the Pro 12Ala variant in the PPAR-gamma2 gene and the response rate to therapy with pioglitazone in patients with type 2 diabetes. Diabetes Care 2003;26:825-31
78. Kirchheiner J, Thomas S, Bauer S, et al. Pharmacokinetics and pharmacodynamics of rosiglitazone in relation to CYP2C8 genotype. Clin Pharmacol Ther 2006;80:657-67
79. Tornio A, Niemi M, Neuvonen PJ, et al. Trimethoprim and the CYP2C8*3 allele have opposite effects on the pharmacokinetics of pioglitazone. Drug Metab Dispos 2008;36:73-80
80. Chang C, Pang KS, Swaan PW, et al. Comparative pharmacophore modeling of organic anion transporting polypeptides: a meta-analysis of rat Oatp1a1 and human OATP1B1. J Pharmacol Exp Ther 2005;314:533-41
81. Nozawa T, Sugiura S, Nakajima M, et al. Involvement of organic anion transporting polypeptides in the transport of troglitazone sulfate: implications for understanding troglitazone hepatotoxicity. Drug Metab Dispos 2004;32:291-4
82. Shitara Y, Hirano M, Sato H, et al. Gemfibrozil and its glucuronide inhibit the organic anion transporting polypeptide 2 (OATP2/ OATP1B1:SLC21A6)-mediated hepatic uptake and CYP2C8-mediated metabolism of cerivastatin: analysis of the mechanism of the clinically relevant drug-drug interaction between cerivastatin and gemfibrozil. J Pharmacol Exp Ther 2004;311:228-36
83. Jaakkola T, Backman JT, Neuvonen M, et al. Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics of pioglitazone. Clin Pharmacol Ther 2005;77:404-14
84. Deng LJ, Wang F, Li HD. Effect of gemfibrozil on the pharmacokinetics of pioglitazone. Eur J Clin Pharmacol 2005;61:831-6
85. Aquilante CL, Bushman LR, Knutsen SD, et al. Influence of SLCO1B1 haplotype on rosiglitazone pharmacokinetics in healthy volunteers. Clin Pharmacol Ther 2008;83:S70
86. Amaryl Prescribing Information. Aventis Pharmaceuticals, Inc.; 2005
87. Glucotrol Prescribing Information. Pfizer; 2006
88. Diabeta Prescribing Information. Aventis Pharmaceuticals, Inc; 2007
89. Marchetti P, Navalesi R. Pharmacokinetic-pharmacodynamic relationships of oral hypoglycaemic agents. An update. Clin Pharmacokinet 1989;16:100-28
90. Satoh H, Yamashita F, Tsujimoto M, et al. Citrus juices inhibit the function of human organic anion-transporting polypeptide OATP-B. Drug Metab Dispos 2005;33:518-23
91. Golstein PE, Boom A, van Geffel J, et al. P-glycoprotein inhibition by glibenclamide and related compounds. Pflugers Arch 1999;437:652-60
92. Gedeon C, Behravan J, Koren G, et al. Transport of glyburide by placental ABC transporters: implications in fetal drug exposure. Placenta 2006;27:1096-102
93. Lilja JJ, Niemi M, Fredrikson H, et al. Effects of clarithromycin and grapefruit juice on the pharmacokinetics of glibenclamide. Br J Clin Pharmacol 2007;63:732-40
94. Semple CG, Omile C, Buchanan KD, et al. Effect of oral verapamil on glibenclamide stimulated insulin secretion. Br J Clin Pharmacol 1986;22:187-90
95. Niemi M, Backman JT, Neuvonen M, et al. Effects of rifampin on the pharmacokinetics and pharmacodynamics of glyburide and glipizide. Clin Pharmacol Ther 2001;69:400-6
96. Zerilli T, Pyon EY. Sitagliptin phosphate: a DPP-4 inhibitor for the treatment of type 2 diabetes mellitus. Clin Ther 2007;29:2614-34
97. Januvia Prescribing Information. Merck & Co., Inc.; 2007
98. Herman GA, Stevens C, Van Dyck K, et al. Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses. Clin Pharmacol Ther 2005;78:675-88
99. Chu XY, Bleasby K, Yabut J, et al. Transport of the dipeptidyl peptidase-4 inhibitor sitagliptin by human organic anion transporter 3, organic anion transporting polypeptide 4C1, and multidrug resistance P-glycoprotein. J Pharmacol Exp Ther 2007;321:673-83
100. Precose Prescribing Information. Bayer Pharmaceuticals Corporation; 2004
101. Glyset Prescribing Information. Pfizer; 2006
102. Florez JC, Jablonski KA, Bayley N, et al. TCF7L2 polymorphisms and progression to diabetes in the Diabetes Prevention Program. N Engl J Med 2006;355:241-50
103. Ertunc D, Tok EC, Aktas A, et al. The importance of IRS-1 Gly972Arg polymorphism in evaluating the response to metformin treatment in polycystic ovary syndrome. Hum Reprod 2005;20:1207-12
104. Pearson ER, Starkey BJ, Powell RJ, et al. Genetic cause of hyperglycaemia and response to treatment in diabetes. Lancet 2003;362:1275-81
105. Kang ES, Park SY, Kim HJ, et al. Effects of Pro12Ala polymorphism of peroxisome proliferator-activated receptor gamma2 gene on rosiglitazone response in type 2 diabetes. Clin Pharmacol Ther 2005;78:202-8
106. Snitker S, Watanabe RM, Ani I, et al. Changes in insulin sensitivity in response to troglitazone do not differ between subjects with and without the common, functional Pro12Ala peroxisome proliferator-activated receptor-gamma2 gene variant: results from the Troglitazone in Prevention of Diabetes (TRIPOD) study. Diabetes Care 2004;27:1365-8
107. Kang ES, Park SY, Kim HJ, et al. The influence of adiponectin gene polymorphism on the rosiglitazone response in patients with type 2 diabetes. Diabetes Care 2005;28:1139-44
108. Wang G, Wang X, Zhang Q, et al. Response to pioglitazone treatment is associated with the lipoprotein lipase S447X variant in subjects with type 2 diabetes mellitus. Int J Clin Pract 2007;61:552-7
109. Kang ES, Cha BS, Kim HJ, et al. The 11482G >A polymorphism in the perilipin gene is associated with weight gain with rosiglitazone treatment in type 2 diabetes. Diabetes Care 2006;29:1320-4
110. Hansen L, Echwald SM, Hansen T, et al. Amino acid polymorphisms in the ATP-regulatable inward rectifier Kir6.2 and their relationships to glucose- and tolbutamide-induced insulin secretion, the insulin sensitivity index, and NIDDM. Diabetes 1997;46:508-12
111. Sesti G, Marini MA, Cardellini M, et al. The Arg972 variant in insulin receptor substrate-1 is associated with an increased risk of secondary failure to sulfonylurea in patients with type 2 diabetes. Diabetes Care 2004;27:1394-98
112. Meirhaeghe A, Helbecque N, Cottel D, et al. Impact of sulfonylurea receptor 1 genetic variability on non-insulin-dependent diabetes mellitus prevalence and treatment: a population study. Am J Med Genet 2001;101:4-8
113. Rafiq M, Flanagan SE, Patch AM, et al. Effective treatment with oral sulfonylureas in patients with diabetes due to sulfonylurea receptor 1 (SUR1) mutations. Diabetes Care 2008;31:204-9
114. Hansen T, Echwald SM, Hansen L, et al. Decreased tolbutamide-stimulated insulin secretion in healthy subjects with sequence variants in the high-affinity sulfonylurea receptor gene. Diabetes 1998;47:598-605
115. Hansen T, Ambye L, Grarup N, et al. Genetic variability of the SUR1 promoter in relation to beta-cell function and Type II diabetes mellitus. Diabetologia 2001;44:1330-4
116. Andrulionyte L, Kuulasmaa T, Chiasson JL, et al. Single nucleotide polymorphisms of the peroxisome proliferator-activated receptor-alpha gene (PPARA) influence the conversion from impaired glucose tolerance to type 2 diabetes: the STOP-NIDDM trial. Diabetes 2007;56:1181-6
117. Andrulionyte L, Zacharova J, Chiasson JL, et al. Common polymorphisms of the PPAR-gamma2 (Pro12Ala) and PGC-1alpha (Gly482Ser) genes are associated with the conversion from impaired glucose tolerance to type 2 diabetes in the STOP-NIDDM trial. Diabetologia 2004;47:2176-84
118. Andrulionyte L, Laukkanen O, Chiasson JL, et al. Single nucleotide polymorphisms of the HNF4alpha gene are associated with the conversion to type 2 diabetes mellitus: the STOP-NIDDM trial. J Mol Med 2006;84:701-8
119. Zacharova J, Chiasson JL, Laakso M. The common polymorphisms (single nucleotide polymorphism [SNP] +45 and SNP +276) of the adiponectin gene predict the conversion from impaired glucose tolerance to type 2 diabetes: the STOP-NIDDM trial. Diabetes 2005;54:893-9
120. Zacharova J, Todorova BR, Chiasson JL, et al. The G-250A substitution in the promoter region of the hepatic lipase gene is associated with the conversion from impaired glucose tolerance to type 2 diabetes: the STOP-NIDDM trial. J Intern Med 2005;257:185-93